Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

87
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
87
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

86
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01).

Journal of hepato-biliary-pancreatic sciences·2026
Same author

Prevalence of and factors associated with radiographic sacroiliitis in Japanese patients with inflammatory bowel disease: a computed tomography-based study.

Modern rheumatology·2026
Same author

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study.

Journal of gastroenterology·2026
Same author

Comparative efficiency of leucine-rich alpha-2 glycoprotein and fecal calprotectin to assess endoscopic activity in Crohn's disease: a prospective observational study.

Inflammatory bowel diseases·2026
Same author

A subepithelial tumor-like lesion in the colon: An unusual manifestation of esophageal squamous cell carcinoma.

Gastroenterologia y hepatologia·2026
Same author

Relative importance of weight gain among cardiometabolic risk factors in the development of metabolic dysfunction-associated steatotic liver disease: An observational study using large-scale health examination data.

Internal medicine (Tokyo, Japan)·2026

Related Experiment Video

Updated: Jun 29, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

Identification of the Microbiome Associated with Prognosis in Patients with Chronic Liver Disease.

Kenta Yamamoto1, Takashi Honda1, Yosuke Inukai1

  • 1Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan.

Microorganisms
|March 28, 2024
PubMed
Summary

Gut microbiome and clinical factors significantly impact chronic liver disease prognosis. Specific bacteria like Ruminococcaceae and Veillonella, along with Barcelona Clinic Liver Cancer staging and cholesterol levels, are key mortality predictors.

Keywords:
6S ribosomal RNA sequencingBarcelona Clinic Liver Cancer stagingCox proportional hazards modelIncertae sedisVeillonellachronic liver diseasesgut microbiomegut–liver axishepatocellular carcinomaprognostic factors

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

11.8K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Related Experiment Videos

Last Updated: Jun 29, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

11.8K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Area of Science:

  • Gastroenterology and Hepatology
  • Microbiome Research
  • Oncology

Background:

  • Chronic liver disease, including hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), poses significant mortality risks.
  • Prognostic factors for chronic liver disease are complex, involving both clinical and potentially microbial elements.

Purpose of the Study:

  • To investigate the prognostic value of gut microbiome composition and clinical factors in patients with chronic liver disease.
  • To identify specific microbial and clinical markers that predict mortality in this patient population.

Main Methods:

  • Utilized data from 227 chronic liver disease patients, including stool samples collected over 3 years.
  • Employed 16S ribosomal RNA sequencing for microbiome analysis and Cox proportional hazards modeling to integrate clinical and microbial data.

Main Results:

  • Hepatocellular carcinoma (HCC) was the primary cause of mortality.
  • Advanced Barcelona Clinic Liver Cancer staging (B/C) and low cholesterol levels (< 140 mg/dL) were associated with increased mortality risk.
  • Specific gut bacteria, including a protective effect from Ruminococcaceae and increased risk from Veillonella, were identified as independent prognostic factors.

Conclusions:

  • Gut microbiome composition, alongside clinical factors like staging and cholesterol, offers independent prognostic significance in chronic liver disease.
  • Integrating microbiome data with clinical attributes can potentially improve patient prognosis and guide treatment strategies for chronic liver disease.